11
RESEARCH BRIEFS
What’ s good for the heart is good for the brain
Early dietary intake of fish improves asthma outlook
Vocal athletes prone to laryngeal injuries
PHYSICAL fitness during middle age likely protects women against dementia, a study suggests.
Swedish researchers ranked the cardiovascular fitness of 191 women with an average age of 50 and checked for dementia over the next 44 years.
Among those originally deemed the most fit on an exercise bike test, only 5 % developed dementia, compared with 25 % of moderately fit women and 32 % of women with low levels of fitness. Among women failing to finish the test, 45 % developed dementia. Neurology 2018, online 14 March
CHILDREN who start eating fish from an early age— as young as six months— have a reduced likelihood of developing wheeze and asthma, an Australian meta-analysis shows.
Data from 23 observational studies suggests that protective behaviours include eating fish at least once a week during childhood and choosing fatty fish, which boosts omega-3 fatty acids relative to omega-6s.
Six of the studies, however, found no effect on asthma from fish consumption and two studies found adverse effects, the researchers said. Paediatr Allergy Immunol 2018; online 9 March
PROFESSIONAL singers have a higher than average risk of a range of laryngeal pathologies and vocal cord symptoms, a meta-analysis shows.
Sydney surgeons analysed 21 studies, finding professional singers had double the risk of developing hoarseness, Reinke edema and polyps, and 1.5 times the risk of gastro-oesphageal reflux disease.
Performers’ risk varied with posture, stress, venue acoustics and allergens, as well as personal eating habits. Singers ranged from opera stars to Muslim and Catholic preachers. J Voice 2018; in press
1
PBS Information: This product is listed on the National Immunisation Programme( NIP) for children only and is not listed on the PBS. Refer to the NIP Schedule.
Please review full Product Information before prescribing. Product Information is available on request on 1800 675 229 or at www. pfizer. com. au
Indications: Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children from 6 weeks of age. Dose: 0.5 mL I. M. Infants 6 weeks to 6 months of age: 3 doses at least one month apart. A single booster should be given in the second year, at least 2 months after the primary series. Previously unvaccinated children: Varies with age at first dose, see full PI. Children previously vaccinated with Prevenar( 7vPCV): Children 12 months to 5 years who have completed primary infant immunisation with 7vPCV and children 6 to 17 years who have received one or more doses of 7vPCV may receive 1 dose, at least 8 weeks after the final dose of 7vPCV. Adults: 1 dose. Special Populations( higher risk, e. g. HIV, SCD): 1 dose. HSCT: 4 doses. If sequential administration of Prevenar 13 and 23vPPV is considered, give Prevenar 13 first. Contraindications: Hypersensitivity to any component of the vaccine, including diphtheria toxoid. Allergic or anaphylactic reaction following prior administration of 7vPCV. Precautions: Do not administer intravenously, intravascularly, intradermally or subcutaneously. Avoid injecting into or near nerves or blood vessels. Do not inject into gluteal area. Postpone administration in acute, moderate or severe febrile illness. Only protects against Streptococcus pneumoniae serotypes included in the vaccine and may not protect all individuals from pneumococcal disease. Consider the risks of I. M injection in infants or children with thrombocytopenia or any coagulation disorder. Appropriate treatment and supervision must be readily available in case of a rare anaphylactic event. Prophylactic antipyretic medication is recommended for children receiving concomitant whole-cell pertussis vaccines, and for children with seizure disorders or history of febrile seizures. Consider the potential risk of apnoea when administering to very premature infants. Very Common / Common Adverse Effects: Children 6 weeks to 5 years: Injection site reactions( redness, pain, swelling), fever, diarrhoea, vomiting, decreased appetite, drowsiness / increased sleep; restless sleep / decreased sleep, rash, irritability. Children and adolescents 5 to 17 years: Irritability, Injection site reactions( redness, pain, swelling), somnolence, poor quality sleep, injection site tenderness( including impaired movement), fever, decreased appetite, vomiting, diarrhoea, headaches, rash. Adults: Diarrhoea, vomiting, nausea, chills, fatigue, injection site reactions( redness, pain, swelling), limitation of arm movement, fever, new or aggravated joint or muscle pain, decreased appetite, headaches, rash. Adults > 65 years reported fewer adverse effects than younger adults. Adverse effects were generally most common in young adults 18 to 29 years. See full PI for details( V10516). References: 1. PREVENAR 13 ® Approved Product Information. ® Registered trademark. Pfizer Australia Pty Limited, 38 – 42 Wharf Road, West Ryde, NSW 2114. PP-PNA-AUS-0060. S & H 02 / 18 PFA2435HP / MO-F